Caiyun Zheng1,2, Hengfen Dai3, Jungao Huang4, Meimei Lin1, Qiaowen Zheng1, Pujing Tang1, Jingwen Xiao3, Yan Zhang3. 1. Affiliated Fuqing City Hospital of Fujian Medical University Fuzhou 350300, China. 2. Fujian Medical University Fuzhou 350122, China. 3. Fuzhou First Hospital Fuzhou 350009, China. 4. Ganzhou Maternal and Child Health Hospital Ganzhou 341000, China.
Abstract
OBJECTIVE: A meta-analysis of the studies involving Sacubitril/Valsartan in chronic heart failure was performed to compare the efficacy and safety of Sacubitril/Valsartan with traditional drug therapy in chronic heart failure. METHODS: We searched databases from PubMed, EMBASE, the Cochrane Library, Web of Science, and clinicaltrials.gov for studies published between 2010 and 2020 that reported efficacy and safety following Sacubitril/Valsartan administration. RESULTS: Ten studies enrolling 1689 patients were included. Sacubitril/Valsartan outperformed traditional medicine (especially the Non-ARNI group) in terms of blood pressure, biomarkers and cardiac reverse remodeling indices, with striking changes in left ventricular ejection fraction, systolic blood pressure. Sacubitril/Valsartan showed significant benefit in renal function in patients with chronic heart failure. CONCLUSIONS: Compared with traditional drugs, Sacubitril/Valsartan significantly improved echocardiography, vital signs and biomarkers of patients with chronic heart failure, and reduced the incidence of hyperkalemia, renal dysfunction and other adverse reactions. Further large sample trials are needed in the future to determine the long-term effects of Sacubitril/Valsartan on efficacy and safety in patients with chronic heart failure. AJTR
OBJECTIVE: A meta-analysis of the studies involving Sacubitril/Valsartan in chronic heart failure was performed to compare the efficacy and safety of Sacubitril/Valsartan with traditional drug therapy in chronic heart failure. METHODS: We searched databases from PubMed, EMBASE, the Cochrane Library, Web of Science, and clinicaltrials.gov for studies published between 2010 and 2020 that reported efficacy and safety following Sacubitril/Valsartan administration. RESULTS: Ten studies enrolling 1689 patients were included. Sacubitril/Valsartan outperformed traditional medicine (especially the Non-ARNI group) in terms of blood pressure, biomarkers and cardiac reverse remodeling indices, with striking changes in left ventricular ejection fraction, systolic blood pressure. Sacubitril/Valsartan showed significant benefit in renal function in patients with chronic heart failure. CONCLUSIONS: Compared with traditional drugs, Sacubitril/Valsartan significantly improved echocardiography, vital signs and biomarkers of patients with chronic heart failure, and reduced the incidence of hyperkalemia, renal dysfunction and other adverse reactions. Further large sample trials are needed in the future to determine the long-term effects of Sacubitril/Valsartan on efficacy and safety in patients with chronic heart failure. AJTR
Authors: Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Melissa A Daubert; Kirkwood Adams; Eric Yow; Huiman X Barnhart; Pamela S Douglas; Susan Rimmer; Casey Norris; Lawton Cooper; Eric Leifer; Patrice Desvigne-Nickens; Kevin Anstrom; Mona Fiuzat; Justin Ezekowitz; Daniel B Mark; Christopher M O'Connor; James Januzzi; G Michael Felker Journal: JACC Heart Fail Date: 2019-01-02 Impact factor: 12.035
Authors: Scott D Solomon; John J V McMurray; Inder S Anand; Junbo Ge; Carolyn S P Lam; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Margaret M Redfield; Jean L Rouleau; Dirk J van Veldhuisen; Faiez Zannad; Michael R Zile; Akshay S Desai; Brian Claggett; Pardeep S Jhund; Sergey A Boytsov; Josep Comin-Colet; John Cleland; Hans-Dirk Düngen; Eva Goncalvesova; Tzvetana Katova; Jose F Kerr Saraiva; Małgorzata Lelonek; Bela Merkely; Michele Senni; Sanjiv J Shah; Jingmin Zhou; Adel R Rizkala; Jianjian Gong; Victor C Shi; Martin P Lefkowitz Journal: N Engl J Med Date: 2019-09-01 Impact factor: 91.245
Authors: John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile Journal: N Engl J Med Date: 2014-08-30 Impact factor: 91.245
Authors: James L Januzzi; Margaret F Prescott; Javed Butler; G Michael Felker; Alan S Maisel; Kevin McCague; Alexander Camacho; Ileana L Piña; Ricardo A Rocha; Amil M Shah; Kristin M Williamson; Scott D Solomon Journal: JAMA Date: 2019-09-17 Impact factor: 56.272
Authors: Milton Packer; John J V McMurray; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael Zile; Karl Andersen; Juan Luis Arango; J Malcolm Arnold; Jan Bělohlávek; Michael Böhm; Sergey Boytsov; Lesley J Burgess; Walter Cabrera; Carlos Calvo; Chen-Huan Chen; Andrej Dukat; Yan Carlos Duarte; Andrejs Erglis; Michael Fu; Efrain Gomez; Angel Gonzàlez-Medina; Albert A Hagège; Jun Huang; Tzvetana Katova; Songsak Kiatchoosakun; Kee-Sik Kim; Ömer Kozan; Edmundo Bayram Llamas; Felipe Martinez; Bela Merkely; Iván Mendoza; Arend Mosterd; Marta Negrusz-Kawecka; Keijo Peuhkurinen; Felix J A Ramires; Jens Refsgaard; Arvo Rosenthal; Michele Senni; Antonio S Sibulo; José Silva-Cardoso; Iain B Squire; Randall C Starling; John R Teerlink; Johan Vanhaecke; Dragos Vinereanu; Raymond Ching-Chiew Wong Journal: Circulation Date: 2014-11-17 Impact factor: 29.690
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: Daria V Ilatovskaya; Vladislav Levchenko; Kristen Winsor; Gregory R Blass; Denisha R Spires; Elizaveta Sarsenova; Iuliia Polina; Adrian Zietara; Mark Paterson; Alison J Kriegel; Alexander Staruschenko Journal: JCI Insight Date: 2022-05-09